Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk

Despite recent advances in the development of tools to predict immunogenicity risk of biotherapeutic molecules, the ability of a protein to elicit the formation of anti-drug antibodies (ADA) remains one of the most common causes for termination of clinical development programs. In this study, we use...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Principais autores: Bivi, Nicoletta, Moore, Terry, Rodgers, George, Denning, Heather, Shockley, Travis, Swearingen, Craig A., Gelfanova, Valentina, Calderon, Boris, Peterson, Daniel A., Hodsdon, Michael E., Siegel, Robert W., Higgs, Richard E., Konrad, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2019
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6601536/
https://ncbi.nlm.nih.gov/pubmed/31099718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1612699
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados